

PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti: Práce je původní a nebyla publikována ani není zaslána k recenznímu řízení do jiného média. **Podíl autorů:** MS: Veškerá práce na manuskriptu **Střet zájmů:** Žádný. **Financování:** Ne. **Registrace v databázích:** N/A. **Projednání etickou komisí:** N/A.

LITERATURA

- Šitina M, Šrámek V. Pathogenesis of euglycemic ketoacidosis associated with SGLT2 inhibitors. *Anesteziol Intenziv Medicína*. 2024;35(2):98-103. doi:10.36290/aim.2024.018
- Šitina M, Šrámek V. Euglycemic ketoacidosis associated with SGLT2 inhibitors and DPP4 inhibitors - discussion of case reports. *Anesteziol Intenziv Medicína*. 2024;35(2):116-121. doi:10.36290/aim.2024.019
- Durán-Martínez M, Azriel S, Doulatram-Gamgaram VK, et al. Real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes in Spain: The Dapa-ON multicenter retrospective study. *Diabetes Metab*. 2024;50(1):101501. doi:10.1016/j.diabet.2023.101501
- Raven LM, Muir CA, Greenfield JR. Sodium glucose cotransporter 2 inhibitor-induced ketoacidosis is unlikely in patients without diabetes. *Med J Aust*. 2023;219(7):293-294. doi:10.5694/mja2.52067
- Umapathysivam MM, Gunton J, Stranks SN, Jesudason D. Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium-Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction. *Diabetes Care*. 2024;47(1):140-143. doi:10.2337/dc23-1163
- Hayes AG, Raven LM, Viardot A, Kotlyar E, Greenfield JR. SGLT2 Inhibitor-Induced Ketoacidosis in a Patient Without Diabetes. *Diabetes Care*. 2024;47(1):e4-e5. doi:10.2337/dc23-1903
- Seki H, Watanabe H, Yorozu T. Postoperative Ketoacidosis With Hypoglycemia in a Nondiabetic Patient Taking Dapagliflozin for Heart Failure: A Case Report. *AA Pract*. 2022;16(3):e01570. doi:10.1213/XAA.0000000000001570
- Iesaka H, Nomoto H, Atsumi T. Alcoholic Ketoacidosis Manifesting With Hypoglycemia Exacerbated by an SGLT2 Inhibitor in a Nondiabetic Patient. *Mayo Clin Proc*. 2023;98(6):947-948. doi:10.1016/j.mayocp.2023.04.003
- Hamblin PS, Wong R, Ekinici EI, et al. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission. *J Clin Endocrinol Metab*. 2019;104(8):3077-3087. doi:10.1210/je.2019-00139
- Šitina M, Šrámek V. Perioperative management in patients treated with gliflozins. *Anesteziol Intenziv Medicína*. 2024(3). <https://www.aimjournal.cz/getrevsrc.php?identification=public&mag=aim&raid=253&type=fin&ver=3>
- Huang CW, Lee JS, Lee MS. Rates of diabetic ketoacidosis with empagliflozin use during hospitalization for acute heart failure. *J Hosp Med*. 2024;19(2):116-119. doi:10.1002/jhm.13268
- Cox ZL, Collins SP, Hernandez GA, et al. Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure. *J Am Coll Cardiol*. 2024;83(14):1295-1306. doi:10.1016/j.jacc.2024.02.009
- Kuchay MS, Khatana P, Mishra M, et al. Dapagliflozin for inpatient hyperglycemia in cardiac surgery patients with type 2 diabetes: randomised controlled trial (Dapa-Hospital trial). *Acta Diabetol*. 2023;60(11):1481-1490. doi:10.1007/s00592-023-02138-4
- Moady G, Yakubovich I, Atar S. Safety and Efficacy of Early SGLT2 Inhibitors Initiation in Diabetic Patients Following Acute Myocardial Infarction, a Retrospective Study. *J Cardiovasc Pharmacol Ther*. 2024;29:10742484241252474. doi:10.1177/10742484241252474
- Von Lewinski D, Kolesnik E, Aziz F, et al. Timing of SGLT2i initiation after acute myocardial infarction. *Cardiovasc Diabetol*. 2023;22(1):269. doi:10.1186/s12933-023-02000-5
- Singh LG, Ntelis S, Siddiqui T, Seliger SL, Sorkin JD, Spanakis EK. Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study. *Diabetes Care*. 2024;47(6):933-940. doi:10.2337/dc23-1129
- Huang W, Whitelaw J, Kishore K, et al. The epidemiology of ketosis and low bicarbonate concentration in inpatients treated with sodium-glucose linked cotransporter inhibitors or dipeptidyl peptidase-4 inhibitors. *J Diabetes Complications*. 2023;37(8):108522. doi:10.1016/j.jdiacomp.2023.108522
- Pérez-Belmonte LM, Sanz-Cánovas J, Millán-Gómez M, et al. Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure. *J Am Geriatr Soc*. 2022;70(3):862-871. doi:10.1111/jgs.17585
- Abani O, Abbas A, Abbas F, et al. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet Diabetes Endocrinol*. 2023;11(12):905-914. doi:10.1016/S2213-8587(23)00253-X
- Mårtensson J, Bellomo R. Sodium-glucose co-transporter-2 inhibitors in the intensive care unit setting: do we really need sodium increase, especially in sepsis? Reply. *Crit Care Lond Engl*. 2023;27(1):225. doi:10.1186/s13054-023-04513-7



FACEBOOK

<https://www.facebook.com/SolenMedicalEducation/>

@SolenMedicalEducation



X

<https://twitter.com/MedicalSolen>

@MedicalSolen



LINKEDIN

<https://www.linkedin.com/company/solen-medical-education/>

#solenmedicaleducation

» ODEMČENÉ **AKTUÁLNÍ ČLÁNKY**

» **PŘEHLED** O VZDĚLÁVACÍCH AKCÍCH

» UPOZORNĚNÍ NA **ZVÝHODNĚNÉ CENY**

» **SOUTĚŽE** O VSTUPENKY NA KONGRESY

» INFORMACE O **ON-LINE** KURZECH

» NOVINKY V **E-SHOPU**

... a mnoho dalšího

... **nenechte si ujít aktuální informace**
o možnostech medicínského vzdělávání